Real-time enrollment status for this relapsed/refractory b-cell malignancies clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:39 AM UTC
| NCT Number | NCT05780034 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory B-cell Malignancies |
| Phase | Clinical Trial |
| Target Enrollment | 60 participants |
| Active Locations | 9 sites in the US |
| Sponsor | Accutar Biotechnology Inc |
| Last Updated on CT.gov | October 2, 2025 (Oct 2, 2025) |
As of July 13, 2026: Clinical trial NCT05780034 is currently recruiting participants. This clinical trial study for relapsed/refractory b-cell malignancies is actively seeking new participants at 9 locations across the United States. The study is sponsored by Accutar Biotechnology Inc. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05780034 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 9 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05780034 was last updated Oct 2, 2025 (October 2, 2025). HelloStudys verifies this status automatically.